posted on 2016-12-15, 09:27authored byG Gallagher, F. Al-Azzawi, L. P. Walsh, G. Wilson, J. Handley
We have defined a novel ovarian cancer-associated membrane antigen, 14C1, using human monoclonal antibodies derived by EBV-transformation of in situ sensitised patients' B-cells. The pattern of recognition of this antigen by these antibodies suggests that at least three epitopes are discernable. These antibodies can be used to promote the in vitro killing of ovarian cancer cells by activated macrophages and cytokines, implying a role for this antigen in the immunotherapy of ovarian malignancies. Evidence is presented that the 14C1 antigen may have some transmembrane signalling function.
Funding
L.P.W. and G.W. are supported by
the Cancer Research Campaign. Additional funds were generously
provided by the East Anglia Regional Health Authority. The anti-
14C1 antibodies described in this report are the property of University
of Strathclyde;
History
Citation
British Journal of Cancer (1991) 64, 35–40.
Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cancer Studies and Molecular Medicine